Grace Therapeutics
GRCE
13 hedge funds and large institutions have $190K invested in Grace Therapeutics in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, reducing their positions, and 2 closing their positions.
662% more capital invested
Capital invested by funds: $24.9K → $190K (+$165K)
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
30% more funds holding
Funds holding: 10 → 13 (+3)
0.13% more ownership
Funds ownership: 0.02% → 0.15% (+0.13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TPCW
TD Private Client Wealth
New York
|
+$143K |
| 2 |
Renaissance Technologies
New York
|
+$54.1K |
| 3 |
VF
Virtu Financial
New York
|
+$13.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.23K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.08K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCC
Money Concepts Capital
Palm Beach Gardens,
Florida
|
-$94 |
| 2 |
BlackRock
New York
|
-$31 |
GRCE Hedge Fund Activity: Q1 2023 in Review
13 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q1 2023, worth a combined $190K — up 662% from $24.9K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new GRCE positions and 2 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was TD Private Client Wealth, opening a new position worth an estimated $143K. The largest seller was Money Concepts Capital, exiting entirely with an estimated $94 sold.
- 13 institutional investors held Grace Therapeutics (GRCE) as of Q1 2023, up from 10 in Q4 2022.
- Funds reported $190K of Grace Therapeutics stock for Q1 2023, up 662% quarter-over-quarter.
- 5 funds opened new Grace Therapeutics positions in Q1 2023 and 2 closed out, a net change of +3 holders.
- The largest Grace Therapeutics buyer in Q1 2023 was TD Private Client Wealth, an estimated $143K added.
- The largest Grace Therapeutics seller in Q1 2023 was Money Concepts Capital, an estimated $94 sold.
Based on aggregated 13F filings for Q1 2023.